Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection

J Antimicrob Chemother. 2014 May;69(5):1436-9. doi: 10.1093/jac/dkt530. Epub 2014 Jan 23.
No abstract available

Keywords: multidrug resistance; raltegravir and maraviroc dosing; simplification.

Publication types

  • Letter

MeSH terms

  • Cyclohexanes / therapeutic use*
  • Drug Resistance, Viral
  • Female
  • HIV Infections / drug therapy*
  • HIV-1 / drug effects
  • HIV-1 / genetics
  • HIV-1 / isolation & purification*
  • Humans
  • Male
  • Maraviroc
  • Middle Aged
  • Mutation, Missense
  • Pyrrolidinones / therapeutic use*
  • Raltegravir Potassium
  • Treatment Failure
  • Triazoles / therapeutic use*
  • Viral Load*

Substances

  • Cyclohexanes
  • Pyrrolidinones
  • Triazoles
  • Raltegravir Potassium
  • Maraviroc